Mesothelioma

BAP1 loss was associated with improved clinical outcomes following immunotherapy in PM. These findings support that a molecular profile that includes BAP1 deletion may serve as a biomarker for predicting response to immunotherapy in PM.

P1, N=41, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons. The decision was not based on any safety concerns.

Our study demonstrates recurrent activation of AKT kinases by copy number gains and upregulated expression in PM. Pharmacological AKT and mTOR inhibition is a promising therapeutic alternative for mesothelioma.

CD155 may serve as a poor prognostic factor in mesothelioma and represents the first immunohistochemical evaluation of this marker. Although CD73 and CD155 co-expression were initially predicted to indicate poor prognosis, findings were unexpected, likely due to inability to establish an optimal cutoff value given variations in patient demographics, disease stage, and treatment approaches.

These data provide a comprehensive overview on the prevalence on homozygous and heterozygous 9p21 deletions in cancer and demonstrate that different cancer types markedly differ in their ratio of homozygous/heterozygous 9p21 deletions. The strong concordance between homozygous 9p21 deletions and absent MTAP immunostaining highlights the effectiveness of immunohistochemistry in detecting MTAP deficiency.

CTLA4 polymorphisms may play a role in the susceptibility for asbestos-related diseases. Our results may contribute to a better understanding of the pathogenesis and progression of asbestos-related diseases.

P2, N=27, Active, not recruiting, Hospices Civils de Lyon | Recruiting --> Active, not recruiting | N=154 --> 27

This case underscores the diagnostic challenges of SM-MPM, particularly in patients presenting with recurrent unexplained ascites and multiple serous effusions. It highlights the importance of maintaining a high index of suspicion and the pivotal role of laparoscopy, immunohistochemistry, and multidisciplinary collaboration in achieving timely diagnosis and optimizing patient outcomes.

P1, N=19, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: May 2029 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2028 --> May 2026; The trial was terminated for strategic reasons. The decision was not based on any safety concerns

P1, N=137, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2026 --> Jan 2027

P1, N=186, Recruiting, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Trial completion date: Jun 2030 --> Jan 2027 | Trial primary completion date: Jan 2030 --> Jan 2027

A total of six cycles of pemetrexed-cisplatin chemotherapy were given and elicited a partial response. The disease progressed and intraperitoneal bevacizumab-cisplatin therapy was administered, which was ineffective...Correct diagnosis is facilitated by an awareness of occupational exposure risk, such as that of asphalt exposure for the present case, and early histopathological evaluation. The prognosis for DPM remains poor despite multimodal therapy, and novel therapeutic strategies are needed.